QuarterHawk — Equity ResearchQuarterHawk — Equity Research

Alignment Healthcare, Inc. (ALHC)

Healthcare

No action
Fundamental
3
Sentiment
2
Technical
2

Do Nothing: qualitativeScore is 2 (below the required floor of 3), so no bullish entry may be issued regardless of chart; the chart itself scores 2/5 (price 7.50 under SMA20 7.86 / SMA50 8.79 / SMA200 16.12, MACD -0.39 < 0), no pullback limit qualifies (countertrend: price < SMA50 with MACD < 0) and no breakout stop qualifies (technicalScore 2 < 3).

Analysis as of 2026-11-13· more than 2 trading days ago

Company overview

Alignment Healthcare, Inc. is a Medicare Advantage provider that operates a consumer-focused healthcare platform. The company offers personalized medical services primarily for elderly individuals across the United States, with operations in California, North Carolina, and Nevada.

Fundamental

fair
Fundamental3
Mixed fundamentals

Alignment Healthcare shows strong revenue growth but faces execution risks and thin margins.

Mixed fundamentals: revenue growth above 30%, positive nine-month 2026 GAAP earnings, net cash and no maturities before 2029, offset by a Q3 2026 margin reversal, negative Q4 adjusted EBITDA guidance and the loss of a half-star on the plan covering ~75% of membership that pressures 2028 quality bonus revenue. At ~0.24x EV/sales versus a $12.29 consensus target the stock is inexpensive, but earnings quality is thin and execution risk is high.

Sentiment

weak
Sentiment2
Bearish sentiment

Sentiment is negative due to adverse earnings, downgrades, and unresolved regulatory issues.

Dominant catalyst is the bearish Q3 2026 print (2026-10-30, announced) — a $8.05m net loss with the profit outlook trimmed even as sales guidance was raised — which triggered a price-target cut cycle plus KeyBanc and Argus downgrades and keeps the name under pressure, alongside an unresolved APA fight with CMS over the 2027 star ratings and a whistleblower accounting-allegation overhang. Sentiment delta is determinate but only mildly positive (baseline polarity -0.52 → scoring -0.32, both windows still negative) with no catalyst leg the tape has actually rewarded; the screen shows no severe flag, but a moderate red-flag cap applied for confirmed material litigation, leaving the setup weak rather than mixed.

Technical

weak
Technical2
Bearish trend

The stock is in a bearish trend with no qualifying entry point for a long position.

Chart quality 2/5 (mostly neutral-to-weak): price 7.50 sits below the SMA20 7.86, SMA50 8.79 and SMA200 16.12 and below EMA9/EMA21, so every trend frame is bearish; RSI 42.32 and Williams %R -63.64 are weak; MACD is below zero (-0.39/-0.46) with a mildly positive histogram (+0.07) — repair rather than reclaim; ADX 26.38 falling means the downtrend is maturing but still intact. Liquidity, ATR (7.07% of price) and the event calendar are all clean, but there is no trend-aligned long: a pullback limit trips the countertrend gate (price < SMA50 and MACD < 0) and a breakout stop lacks the required score. The plan is blocked outright by qualitativeScore 2 < 3 (shadow flag false), so the action is Do Nothing.

You’re looking at 2026-11-13 — more than 2 trading days ago.

Subscribers saw this then, and see today’s score, verdict and trade plan now.

Not financial advice. For informational and educational purposes only.